Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 Sep 10;34(26):3189-94.
doi: 10.1200/JCO.2015.66.1140. Epub 2016 Jul 11.

Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group

Eric J Gratias  1 , Jeffrey S Dome  1 , Lawrence J Jennings  1 , Yueh-Yun Chi  1 , Jing Tian  1 , James Anderson  1 , Paul Grundy  1 , Elizabeth A Mullen  1 , James I Geller  1 , Conrad V Fernandez  1 , Elizabeth J Perlman  2
Affiliations
Multicenter Study

Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group

Eric J Gratias et al. J Clin Oncol. .

Abstract

Purpose: The goal of this study was to analyze the association of copy number gain of 1q in favorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall survival (OS) within each tumor stage and with 1p and 16q copy number loss and/or loss of heterozygosity.

Methods: Unilateral FHWTs from 1,114 patients enrolled in National Wilms Tumor Study-5 that were informative for 1p and 16q microsatellite markers (previously determined) and informative for 1q gain, 1p loss, and 16q loss using multiplex ligation-dependent probe amplification were analyzed.

Results: Eight-year EFS was 86% (95% CI, 84% to 88%) for the entire cohort. Of 1,114 patients, 317 tumors (28%) displayed 1q gain. Eight-year EFS was 77% for those with 1q gain and 90% for those lacking 1q gain (P < .001). Eight-year OS was 88% for those with 1q gain and 96% for those lacking 1q gain (P < .001). Within each disease stage, 1q gain was associated with inferior EFS (stage I, 85% v 95%; P = .0052; stage II, 81% v 87%; P = .0775; stage III, 79% v 89%; P = .01; stage IV, 64% v 91%; P = .001). OS was significantly inferior in patients with stage I (P < .0015) and stage IV disease (P = .011). With multivariable analysis, 1q gain was associated with an increased relative risk of relapse of 2.4 (P < .001), whereas 1p loss was not, despite significance on univariable analysis.

Conclusion: Gain of 1q is associated with inferior survival in unilateral FHWTs and may be used to guide risk stratification in future studies.

PubMed Disclaimer

Conflict of interest statement

Authors’ disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Event-free survival (EFS) stratified for 1q gain.
Fig 2.
Fig 2.
Overall survival (OS) stratified for 1q gain.
See this image and copyright information in PMC

References

    1. Termuhlen AM, Tersak JM, Liu Q, et al. Twenty-five year follow-up of childhood Wilms tumor: A report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2011;57:1210–1216. - PMC - PubMed
    1. Dome JS, Perlman EJ, Graf N. Risk stratification for Wilms tumor: Current approach and future directions. Am Soc Clin Oncol Ed Book. 2014:215–223. - PubMed
    1. Grundy PE, Telzerow PE, Breslow N, et al. Loss of heterozygosity for chromosomes 16q and 1p in Wilms’ tumors predicts an adverse outcome. Cancer Res. 1994;54:2331–2333. - PubMed
    1. Grundy RG, Pritchard J, Scambler P, et al. Loss of heterozygosity on chromosome 16 in sporadic Wilms’ tumour. Br J Cancer. 1998;78:1181–1187. - PMC - PubMed
    1. Klamt B, Schulze M, Thäte C, et al. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters. Genes Chromosomes Cancer. 1998;22:287–294. - PubMed

Publication types

MeSH terms

Substances